179 related articles for article (PubMed ID: 37208678)
1. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract][Full Text] [Related]
2. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers.
O'Neill PA; Davies MP; Shaaban AM; Innes H; Torevell A; Sibson DR; Foster CS
Br J Cancer; 2004 Nov; 91(9):1694-702. PubMed ID: 15477865
[TBL] [Abstract][Full Text] [Related]
3. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
4. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
[TBL] [Abstract][Full Text] [Related]
7. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
[TBL] [Abstract][Full Text] [Related]
8. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
[TBL] [Abstract][Full Text] [Related]
9. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M; Rayoo M; Takano EA; ; Fox SB
Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Hamilton N; Marquez-Garban D; Mah VH; Elshimali Y; Elashoff D; Garon EB; Vadgama J; Pietras R
Crit Rev Oncog; 2015; 20(5-6):373-90. PubMed ID: 27279236
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
13. ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Meligova AK; Siakouli D; Stasinopoulou S; Xenopoulou DS; Zoumpouli M; Ganou V; Gkotsi EF; Chatziioannou A; Papadodima O; Pilalis E; Alexis MN; Mitsiou DJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835157
[TBL] [Abstract][Full Text] [Related]
14. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
15. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy.
Dhimolea E; Tiniakos DG; Chantzi ΝΙ; Goutas N; Vassilaros SD; Mitsiou DJ; Alexis ΜN
Cancer Lett; 2015 Mar; 358(1):37-42. PubMed ID: 25524554
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
18. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
19. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract][Full Text] [Related]
20. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
